Holen Sie sich die Stockscreener-App
199.11
0.33%
-1.87
Ascendis Pharma A S Adr Aktie (ASND) Neueste Nachrichten
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Sahm
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation as Analyst Confidence Rises on Key EMA Filing - Sahm
Looking Into Ascendis Pharma AS's Recent Short Interest - Sahm
How Ascendis Pharma’s (ASND) TransCon CNP EMA Submission Has Shaped Its Rare Disease Investment Story - Sahm
Should Investors Consider Ascendis Pharma After FDA Nod for Next-Gen Hormone Therapy in 2025? - Sahm
Ascendis Pharma A/S Sponsored ADR (ASND) Stock Price Today | Live Chart & News - Traders Union
Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $244.64 - Defense World
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Book value per share of Ascendis Pharma A/S Sponsored ADR – MUN:A71 - TradingView
Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment - Sahm
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia - Sahm
Does Analyst Backing of Yorvipath Shift the Competitive Narrative for Ascendis Pharma (ASND)? - Sahm
Ascendis Pharma increases share capital following warrant exercises - Investing.com
Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts - Investing.com
Ascendis Pharma A/S Q2 Earnings Call Highlights Growth - The Globe and Mail
Stocks To Watch: Sociedad Quimica ADR Sees Relative Strength Rating Rise To 80 - inkl
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 92 - Investor's Business Daily
Ascendis Pharma AS earnings beat by €0.45, revenue topped estimates - Investing.com
Ascendis Pharma stock rating reiterated by Cantor Fitzgerald ahead of Q2 results - Investing.com
Ascendis Pharma ADR Shows Rising Price Performance With Jump To 81 RS Rating - Investor's Business Daily
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail
Ascendis Pharma stock jumps after FDA approves SKYTROFA for adult GHD - Investing.com
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN
Stocks Showing Rising Market Leadership: Gpo Aeroportuario ADR Earns 83 RS Rating - inkl
Ascendis Pharma reports positive results from hypothyroid trial - MSN
Ascendis Pharma stock rating assumed at Overweight by Morgan Stanley - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize
Canaccord holds Ascendis Pharma stock at $84 target - Investing.com
BofA raises Ascendis Pharma stock target to $216 - Investing.com
Ascendis Pharma ADR Scores Relative Strength Rating Upgrade - MSN
Chagee Holdings ADR Scores Relative Strength Rating Upgrade - inkl
BofA Securities raises Ascendis Pharma stock price target to $201 - Investing.com
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
Ascendis Pharma stock rises following FDA priority review By Investing.com - Investing.com India
Ascendis Pharma stock rises following FDA priority review - Investing.com
FDA prioritizes review of Ascendis Pharma’s growth disorder drug - Investing.com
Stifel maintains Buy on Ascendis Pharma stock, target at $212 - Investing.com
Ascendis Pharma’s SWOT analysis: strong product pipeline drives stock potential - Investing.com India
Ascendis Pharma grants new employee warrants By Investing.com - Investing.com India
Ascendis Pharma grants new employee warrants - Investing.com
Ascendis Pharma reports growth in achondroplasia trial By Investing.com - Investing.com India
Ascendis Pharma reports growth in achondroplasia trial - Investing.com
Cantor maintains $200 target on Ascendis Pharma stock By Investing.com - Investing.com South Africa
European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize
In the Green: Ascendis Pharma A/S ADR (ASND) Closes at 160.99, Up/Down -1.14 from Previous Day - DWinneX
Ascendis Pharma stock target raised to $245 by JPMorgan - Investing.com
Ascendis Pharma AS earnings missed by €0.11, revenue topped estimates - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
RBC Capital sets $205 target on Ascendis Pharma stock - Investing.com
0.51%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):